Novo Nordisk has reported Phase III data showing weekly cagrilintide 2.4mg achieved 11.8% weight loss (12.5kg) versus 2.3% for placebo over 68 weeks in obese patients without diabetes, with 31.6% participants exceeding 15% weight reduction. The amylin analogue demonstrated favourable gastrointestinal tolerability with only 1.0% discontinuation due to nausea, supporting potential long-term adherence advantages over GLP-1 agonists. While efficacy trails semaglutide's 16-18% weight reduction in STEP trials, cagrilintide's safety profile positions it for combination approaches and broader patient populations.

Novo Nordisk will initiate a Phase III RENEW trial in Q4 2025 to explore monotherapy applications despite previous focus on cagrilintide + semaglutide that showed 22.7% weight reduction, missing the 25% threshold target. The amylin program gains strategic importance as semaglutide patents approach expiration and Eli Lilly's tirzepatide accelerates market share growth. Recent leadership changes and restructuring eliminating 9,000 jobs reflect intensified competition in obesity therapeutics requiring diversified approaches beyond GLP-1 mechanisms.

PharmCube's NextBiopharm® lists 23 active amylin projects globally, targeting a number of diseases outside obesity and diabetes. Click here to request a free trial for NextBiopharm®.